"Uscom (ASX:UCM) shares went on a run after the company reported...

"Uscom (ASX:UCM) shares went on a run after the company reported increased orders for its haemodynamic monitoring devices in China.Uscom stands for Ultra-Sonic Cardiac Output Monitors.The Uscom 1A device is a non-invasive diagnostic that monitors cardiovascular functions, using Doppler ultrasound to detect abnormalities.Chinese health authorities have recommended Uscom 1A as a monitoring device for severe coronavirus cases, while international guidelines also suggest using the device for paediatric sepsis.Uscom reported that in the first five weeks of 2019, Chinese sales orders rose 124 per cent, from 17 units to 38 units.Uscom chief Professor Rob Phillips says the company is “well positioned” with the virus, but notes that Uscom is not a coronavirus story as such: fatalities from cardiovascular pulmonary failure result from conditions such as pneumonia.Happily for Uscom, the outbreak comes as the company hones-in on the Chinese market with a new direct sales model."

https://**promotion blocked**/health/dr-borehams-crucible-the-small-cap-biotechs-trying-to-make-a-buck-from-coronavirus/

READ: Dr Boreham’s Crucible: Uscom gets an A+ for everything but its share price

"With established sales and a promising route to China, Uscom is a clear candidate for dux of the class (specialist medical device stream).The company’s digital offerings are especially suited to the electronic health sector, which is now being vigorously pursued by the likes of Google, Microsoft, Apple and — speaking of China — Tencent and Huawei."

"Professor Phillips argues the company could make itself profitable now by shelving its growth plans, but he is striving for earnings of perhaps $40m rather than, say, $4m.“Because we have high margin products, profitability will come quite quickly,” he says.“We don’t need to spend any more. We have acquired companies, built offices and established international manufacturing. All of our stuff is done. Our costs should diminish and our revenue should grow.”Uscom’s lowly market cap makes for an intriguing comparison with the ASX-listed Respiri (formerly Isonea and Karmelsonix) which is seeking European approval for its ‘Wheezo’ asthma device.The last time we looked, the pre-revenue Respiri was valued at $36m and a few months ago was worth close to $100m, despite almost continuous board and management changes."